The European Medicines Agency (EMA) has approved additional manufacturing capacity for the Pfizer/BioNTech COVID-19 vaccine in France – increasing production by 51 million doses by the end of… read more.
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy…. read more.
Investigations carried out at the La Jolla institute for Immunology (LJI) Show that the combination of vitamin C and TET proteins are essential for the proper function of… read more.
Takeda Pharmaceutical announced results from two final analyses from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint)… read more.
There has been a rapid rise in the number of human immunodeficiency virus (HIV) infections in China since the dawn of the 21st century. In the recent past,… read more.
Scientists at McMaster University in Toronto have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the… read more.
Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.
Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell… read more.
People who have had mild illness develop antibody-producing cells that can last lifetime Washington University School of Medicine Months after recovering from mild cases of COVID-19, people still… read more.
Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
